HKSE - Delayed Quote • HKD
Livzon Pharmaceutical Group Inc. (1513.HK)
At close: 4:09 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
12,430,038.326
12,430,038.326
12,629,579.048
12,063,863.273
10,520,409.842
Cost of Revenue
4,465,473.361
4,465,473.361
4,461,283.076
4,253,087.484
3,673,710.774
Gross Profit
7,964,564.965
7,964,564.965
8,168,295.972
7,810,775.789
6,846,699.068
Operating Expense
5,533,852.905
5,533,852.905
5,933,892.236
5,623,144.495
4,531,694.460
Operating Income
2,430,712.059
2,430,712.059
2,234,403.736
2,187,631.294
2,315,004.609
Net Non Operating Interest Income Expense
271,501.923
271,501.923
212,078.919
74,323.083
145,196.697
Pretax Income
2,382,666.546
2,382,666.546
2,330,550.610
2,245,688.830
2,489,435.688
Tax Provision
485,065.534
485,065.534
374,973.228
293,587.661
358,108.981
Net Income Common Stockholders
1,953,650.833
1,953,650.833
1,909,407.688
1,775,683.251
1,714,910.390
Basic EPS
2.15
2.10
2.04
1.90
1.83
Diluted EPS
2.15
2.10
2.04
1.90
1.83
Basic Average Shares
932,403.203
930,309.921
935,984.161
934,570.132
937,109.503
Diluted Average Shares
932,403.203
930,309.921
935,984.161
934,570.132
937,109.503
Total Operating Income as Reported
2,415,108.490
2,415,108.490
2,350,555.618
2,266,989.995
2,500,449.170
Total Expenses
9,999,326.267
9,999,326.267
10,395,175.312
9,876,231.979
8,205,405.233
Net Income from Continuing & Discontinued Operation
1,953,650.833
1,953,650.833
1,909,407.688
1,775,683.251
1,714,910.390
Normalized Income
2,231,540.915
2,231,540.915
2,074,001.728
1,845,367.069
1,771,276.027
Interest Income
-368,159.120
-368,159.120
315,137.488
162,189.969
175,564.199
Interest Expense
102,085.923
102,085.923
97,545.934
83,997.235
25,313.177
Net Interest Income
271,501.923
271,501.923
212,078.919
74,323.083
145,196.697
EBIT
2,484,752.469
2,484,752.469
2,428,096.544
2,329,686.064
2,514,748.865
EBITDA
3,325,076.101
3,325,076.101
3,080,420.588
2,774,957.373
2,909,048.444
Reconciled Cost of Revenue
4,465,473.361
4,465,473.361
4,461,283.076
4,253,087.484
3,673,710.774
Reconciled Depreciation
840,323.632
840,323.632
652,324.044
445,271.308
394,299.579
Net Income from Continuing Operation Net Minority Interest
1,953,650.833
1,953,650.833
1,909,407.688
1,775,683.251
1,714,910.390
Total Unusual Items Excluding Goodwill
-348,924.457
-348,924.457
-196,154.213
-80,163.966
-65,836.283
Total Unusual Items
-348,924.457
-348,924.457
-196,154.213
-80,163.966
-65,836.283
Normalized EBITDA
3,674,000.558
3,674,000.558
3,276,574.801
2,855,121.338
2,974,884.726
Tax Rate for Calcs
0.000
0.000
0.000
0.000
0.000
Tax Effect of Unusual Items
-71,034.375
-71,034.375
-31,560.172
-10,480.148
-9,470.646
12/31/2020 - 1/16/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MRKC.MU Merck KGaA
29.60
0.00%
688192.SS Dizal (Jiangsu) Pharmaceutical Co., Ltd.
41.82
+10.99%
2196.HK Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
11.760
-0.51%
300558.SZ Betta Pharmaceuticals Co., Ltd.
38.65
+0.91%
2161.HK JBM (Healthcare) Limited
0.900
-1.10%
0950.HK Lee's Pharmaceutical Holdings Limited
1.160
0.00%
2633.HK Jacobson Pharma Corporation Limited
0.570
0.00%
2877.HK China Shineway Pharmaceutical Group Limited
9.030
-0.77%
3692.HK Hansoh Pharmaceutical Group Company Limited
16.340
+1.87%
1681.HK Consun Pharmaceutical Group Limited
5.600
+0.54%